CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Cytosorbents Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.96+0.85 (+20.68%)
Close on Oct 19, 2026
- Market cap
- $311.52M
- P/E (TTM)
- –
- Dividend yield
- –
Cytosorbents statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Market Cap | $311.70M | $230.55M |
| Enterprise Value | $324.53M | $202.97M |
| PS Ratio | 8.38 | 3.11 |
Enterprise value
| Measure | Cytosorbents | Industry median |
|---|---|---|
| EV / Sales | 8.72 | 2.92 |
Income (trailing twelve months)
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Revenue | $37.22M | $102.39M |
| Gross Profit | $26.65M | $60.36M |
| Operating Income | -$12.93M | -$4.31M |
| Net Income | -$18.21M | -$6.57M |
| EBITDA | -$12.93M | -$1.98M |
| EPS (Diluted) | -$0.29 | -$0.07 |
Margins
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Gross Margin | 71.6% | 55.1% |
| Operating Margin | -34.7% | -6.04% |
| Profit Margin | -48.9% | -10.5% |
| EBITDA Margin | -34.7% | -2.67% |
| FCF Margin | -25.0% | -0.30% |
Returns
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Return on Equity (ROE) | -336.2% | -19.2% |
| Return on Assets (ROA) | -42.4% | -13.3% |
| Return on Invested Capital (ROIC) | -73.4% | -4.11% |
| Return on Capital Employed (ROCE) | -92.8% | -9.07% |
Growth
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3.07% | 8.85% |
| Revenue Growth (3Y CAGR) | 2.23% | 7.08% |
| Revenue Growth (5Y CAGR) | -2.00% | 11.8% |
Balance sheet
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.41M | $37.33M |
| Total Debt | $17.24M | $72.66M |
| Net Cash (Debt) | -$12.83M | $3.92M |
| Net Cash Per Share | -$0.20 | $0.28 |
| Equity (Book Value) | -$751.00K | $57.36M |
| Book Value Per Share | -$0.01 | $2.81 |
| Tangible Book Value | -$3.62M | $10.71M |
| Working Capital | -$8.29M | $54.64M |
Financial position
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Current Ratio | 0.66 | 2.50 |
| Quick Ratio | 0.47 | 1.54 |
Cash flow (trailing twelve months)
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Operating Cash Flow | -$9.15M | -$653.46K |
| Capital Expenditures | -$150.00K | -$3.69M |
| Free Cash Flow | -$9.30M | -$835.02K |
| FCF Per Share | -$0.15 | -$0.02 |
Efficiency
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Asset Turnover | 0.87 | 0.59 |
| Inventory Turnover | 2.86 | 2.21 |
| Revenue Per Employee | $288.50K | $322.57K |
| Profits Per Employee | -$141.19K | -$51.88K |
| Employee Count | 129 | 185 |
Dividends and yields
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Earnings Yield | -5.84% | -6.91% |
| FCF Yield | -2.98% | -0.56% |
Shares
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Shares Outstanding | 62,842,700 | 44,856,700 |
| Shares Change (YoY) | 5.92% | 3.35% |
| Shares Change (QoQ) | 0.17% | 0.27% |
| Float | 61,260,800 | 37,097,900 |
| Shares Held by Insiders | 2.52% | 10.6% |
| Shares Held by Institutions | 25.7% | 63.5% |
Taxes
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Income Tax | -$401.00K | $1.52M |
Scores
| Measure | Cytosorbents | Industry median |
|---|---|---|
| Altman Z-Score | -7.44 | 1.95 |
| Piotroski F-Score | 3 | 5 |
| Beneish M-Score | -2.09 | -2.64 |
Calculated by StockData from Cytosorbents's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.